GC Green Cross Surpasses 600 Billion Won in Quarterly Sales for the First Time Since Founding

GC Green Cross announced on the 3rd that, based on its consolidated financial statements, preliminary sales for the third quarter of this year reached 609.5 billion won. This figure represents a 31.1% increase compared to the same period last year, marking the first time in the company’s history that quarterly sales have surpassed 600 billion won.

During the same period, operating profit was 29.2 billion won, and net profit was 18.1 billion won.

The exterior view of GC Green Cross headquarters in Yongin, Gyeonggi Province. GC Green Cross

The company explained that the continued growth of Aliglo and the expansion of prescription drug sales drove the record-high quarterly sales. In particular, Aliglo, the company’s flagship product, has maintained its growth each quarter this year, achieving a 117% increase in sales compared to the same period last year.

Additionally, GC Green Cross proactively increased Aliglo export volumes in the first half of the year to secure local inventory in response to changes in U.S. tariff policies. In the fourth quarter, the company is shipping next year’s sales volumes.

On a separate basis, sales by business segment were as follows: plasma derivatives at 133.6 billion won, vaccines at 91.9 billion won, prescription drugs at 170.2 billion won, and over-the-counter drugs and consumer healthcare at 34 billion won.

Certain high-margin products were affected by changes in the external environment. The influenza vaccine was switched to a trivalent vaccine starting this year, and Hunterase saw a slight decline due to a base effect, as overseas supply was concentrated in the first half. However, with Hunterase’s cumulative sales in the third quarter already reaching 96% of last year’s annual sales, the company expects double-digit growth for the full year.

Furthermore, ABO Plasma, which GC Green Cross acquired a 100% stake in this January, saw its losses widen compared to the previous quarter due to increased costs from the early opening of the Laredo Plasma Center in Texas, as well as one-time investment expenses aimed at establishing a foundation for mid- to long-term growth.

Subsidiaries included in the consolidated results, which announced their earnings earlier, also showed solid performance.

GC Cell recorded sales of 45 billion won and significantly reduced its operating loss compared to the previous quarter. The company explained that the recovery of major business segments, which continued from the previous quarter, drove this performance improvement.

GC Green Cross MS and GC Green Cross Wellbeing also posted strong results in their core businesses, recording sales of 26.4 billion won and 42.3 billion won, respectively, and generating stable profits.

A GC Green Cross representative stated, "We will continue to strengthen our mid- to long-term growth momentum based on our solid existing businesses."

Meanwhile, GC Green Cross recently secured a contract with its U.S. affiliate Curevo Vaccine for CMO rights to the shingles vaccine "Amezosvataine," establishing a new growth engine for the mid- to long-term. The global shingles vaccine market is currently estimated at around 6 trillion won, and Curevo aims to secure a double-digit market share.